Aug 18 (Reuters) - AzurRx BioPharma Inc :
* AZURRX BIOPHARMA ANNOUNCES POSITIVE TOPLINE DATA FOR PHASE 2 MS1819 COMBINATION THERAPY TRIAL IN CYSTIC FIBROSIS PATIENTS WITH SEVERE EXOCRINE PANCREATIC INSUFFICIENCY $(EPI)$
* AZURRX BIOPHARMA INC - MS1819 AND PERT COMBINATION THERAPY ACHIEVES PRIMARY AND SECONDARY OUTCOME MEASURE ENDPOINTS
* AZURRX BIOPHARMA INC - STUDY DATA INDICATES CLINICALLY MEANINGFUL IMPROVEMENT IN COEFFICIENT OF FAT ABSORPTION $(CFA)$ PRIMARY ENDPOINT
* AZURRX BIOPHARMA INC - 20-PATIENT STUDY SUGGESTS COMBINATION THERAPY MAY BENEFIT CYSTIC FIBROSIS PATIENTS WITH SEVERE EPI
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。